When anti-CSF1 treatment was combined with anti-PD-1/anti-CTLA4 immunotherapy with gemcitabine chemotherapy they observed complete tumor regression in 30% of mice and an average tumor regression of 85% [126]. The gene discussed is CSF1; the disease is neoplasm.